Pyrrolo[3,2-b ]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: Structure-based design, synthesis, and in vivo validation

Journal of Medicinal Chemistry

Volumn 57, Issue 15, 2014, Pages 6834-6844

  Unzue, Andrea ^a   Dong, Jing ^a   Lafleur, Karine ^a   Zhao, Hongtao ^a   Frugier, Emilie ^a   Caflisch, Amedeo ^a   Nevado, Cristina ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PYRROLO[3,2 B]QUINOXALINE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG; EPHRIN RECEPTOR A3; EPHRIN RECEPTOR B4; PYRROLE DERIVATIVE;

ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CANCER TRANSPLANTATION; CHEMISTRY; COMPUTER SIMULATION; DRUG SCREENING; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOLECULAR DOCKING; NUDE MOUSE; THERMODYNAMICS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELL LINE, TUMOR; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROGRAFTS; HUMANS; MALE; MICE, INBRED ICR; MICE, NUDE; MOLECULAR DOCKING SIMULATION; NEOPLASM TRANSPLANTATION; PYRROLES; QUINOXALINES; RECEPTOR, EPHA3; RECEPTOR, EPHB4; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 84906088551     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5009242     Document Type: Article

References (60)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298, 1912-1934
2. Cohen, P. Protein kinases: the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1, 309-315
3. Li, R.; Stafford, J. A. Kinase Inhibitor Drugs; John Wiley & Sons, Inc.: Hoboken, NJ, 2009.
4. Blanc, J.; Geney, R.; Menet, C. Type II kinase inhibitors: an opportunity in cancer for rational design Anticancer Agents Med. Chem. 2013, 13, 731-747
5. Kontzias, A.; Kotlyar, A.; Laurence, A.; Changelian, P.; O'Shea, J. J. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease Curr. Opin. Pharmacol. 2012, 12, 464-470
6. O'Brien, Z.; Moghaddam, M. F. Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data Expert Opin. Drug Metab. Toxicol. 2013, 9, 1597-1612
7. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39
8. Janne, P. A.; Gray, N.; Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors Nat. Rev. Drug Discovery 2009, 8, 709-723
9. Liu, Q. S.; Sabnis, Y.; Zhao, Z.; Zhang, T. H.; Buhrlage, S. J.; Jones, L. H.; Gray, N. S. Developing irreversible inhibitors of the protein kinase cysteinome Chem. Biol. 2013, 20, 146-159
10. Garuti, L.; Roberti, M.; Bottegoni, G. Irreversible protein kinase inhibitors Curr. Med. Chem. 2011, 18, 2981-2994
11. Cozza, G.; Bortolato, A.; Menta, E.; Cavalletti, E.; Spinelli, S.; Moro, S. ATP non-competitive Ser/Thr kinase inhibitors as potential anticancer agents Anticancer Agents Med. Chem. 2009, 9, 778-786
12. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364
13. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors Pharmacol. Ther. 1999, 82, 195-206
14. Huang, D.; Zhou, T.; Lafleur, K.; Nevado, C.; Caflisch, A. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis Bioinformatics 2010, 26, 198-204
15. Bamborough, P.; Drewry, D.; Harper, G.; Smith, G. K.; Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery J. Med. Chem. 2008, 51, 7898-7914
16. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
17. Morphy, R. Selectively nonselective kinase inhibition: striking the right balance J. Med. Chem. 2010, 53, 1413-1437
18. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1046-1051
19. Eglen, R.; Reisine, T. Drug discovery and the human kinome: recent trends Pharmacol. Ther. 2011, 130, 144-156
20. Lafleur, K.; Huang, D.; Zhou, T.; Caflisch, A.; Nevado, C. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4) J. Med. Chem. 2009, 52, 6433-6446
21. Zhao, H. T.; Dong, J.; Lafleur, K.; Nevado, C.; Caflisch, A. Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics ACS Med. Chem. Lett. 2012, 3, 834-838
22. Lafleur, K.; Dong, J.; Huang, D.; Caflisch, A.; Nevado, C. Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography J. Med. Chem. 2013, 56, 84-96
23. Boyd, A. W.; Bartlett, P. F.; Lackmann, M. Therapeutic targeting of EPH receptors and their ligands Nat. Rev. Drug Discovery 2014, 13, 39-62
24. Zhao, H.; Huang, D. Hydrogen bonding penalty upon ligand binding PLoS One 2011, 6, e19923
25. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "gatekeeper door": exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681-2694
26. Bold, G.; Altmann, K. H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Bruggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rosel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lasser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis J. Med. Chem. 2000, 43, 2310-2323
27. Smith, R. A.; Barbosa, J.; Blum, C. L.; Bobko, M. A.; Caringal, Y. V.; Dally, R.; Johnson, J. S.; Katz, M. E.; Kennure, N.; Kingery-Wood, J.; Lee, W.; Lowinger, T. B.; Lyons, J.; Marsh, V.; Rogers, D. H.; Swartz, S.; Walling, T.; Wild, H. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach Bioorg. Med. Chem. Lett. 2001, 11, 2775-2778
28. Khire, U. R.; Bankston, D.; Barbosa, J.; Brittelli, D. R.; Caringal, Y.; Carlson, R.; Dumas, J.; Gane, T.; Heald, S. L.; Hibner, B.; Johnson, J. S.; Katz, M. E.; Kennure, N.; Kingery-Wood, J.; Lee, W.; Liu, X. G.; Lowinger, T. B.; McAlexander, I.; Monahan, M. K.; Natero, R.; Renick, J.; Riedl, B.; Rong, H.; Sibley, R. N.; Smith, R. A.; Wolanin, D. Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent Bioorg. Med. Chem. Lett. 2004, 14, 783-786
29. Albaugh, P.; Fan, Y.; Mi, Y.; Sun, F. X.; Adrian, F.; Li, N. X.; Jia, Y.; Sarkisova, Y.; Kreusch, A.; Hood, T.; Lu, M.; Liu, G. X.; Huang, S. L.; Liu, Z. S.; Loren, J.; Tuntland, T.; Karanewsky, D. S.; Seidel, H. M.; Molteni, V. Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models ACS Med. Chem. Lett. 2012, 3, 140-145
30. Liu, C.; Lin, J.; Wrobleski, S. T.; Lin, S.; Hynes, J.; Wu, H.; Dyckman, A. J.; Li, T.; Wityak, J.; Gillooly, K. M.; Pitt, S.; Shen, D. R.; Zhang, R. F.; McIntyre, K. W.; Salter-Cid, L.; Shuster, D. J.; Zhang, H.; Marathe, P. H.; Doweyko, A. M.; Sack, J. S.; Kiefer, S. E.; Kish, K. F.; Newitt, J. A.; McKinnon, M.; Dodd, J. H.; Barrish, J. C.; Schieven, G. L.; Leftheris, K. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N- propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases J. Med. Chem. 2010, 53, 6629-6639
31. Hynes, J., Jr.; Wu, H.; Pitt, S.; Shen, D. R.; Zhang, R.; Schieven, G. L.; Gillooly, K. M.; Shuster, D. J.; Taylor, T. L.; Yang, X.; McIntyre, K. W.; McKinnon, M.; Zhang, H.; Marathe, P. H.; Doweyko, A. M.; Kish, K.; Kiefer, S. E.; Sack, J. S.; Newitt, J. A.; Barrish, J. C.; Dodd, J.; Leftheris, K. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994): A potent and efficacious p38α MAP kinase inhibitor Bioorg. Med. Chem. Lett. 2008, 18, 1762-1767
32. Wrobleski, S. T.; Lin, S.; Dhar, T. G.; Dyckman, A. J.; Li, T.; Pitt, S.; Zhang, R.; Fan, Y.; Doweyko, A. M.; Tokarski, J. S.; Kish, K. F.; Kiefer, S. E.; Sack, J. S.; Newitt, J. A.; Witmer, M. R.; McKinnon, M.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode Bioorg. Med. Chem. Lett. 2013, 23, 4120-4126
33. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 2005, 7, 129-141
34. Ishikawa, M.; Hashimoto, Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry J. Med. Chem. 2011, 54, 1539-1554
35. Pratt, E. F.; Kereszte, J. Syntheses of indolizino-and dihydroindolizinoquinoxalines J. Org. Chem. 1967, 32, 49-53
36. Obafemi, C. A.; Pfleiderer, W. Synthesis and some reactions of 3-chloro-2-(cyanomethylene)-1,2-dihydroquinoxalines Molecules 2004, 9, 223-231
37. Otomasu, H.; Ohmiya, S.; Sekuguch, T.; Takahash, H. Synthesis of condensed quinoxalines 0.2. A new synthesis of pyrrolo-2,3-b-quinoxalines Chem. Pharm. Bull. 1970, 18, 2065
38. Choi, H. G.; Ren, P.; Adrian, F.; Sun, F.; Lee, H. S.; Wang, X.; Ding, Q.; Zhang, G.; Xie, Y.; Zhang, J.; Liu, Y.; Tuntland, T.; Warmuth, M.; Manley, P. W.; Mestan, J.; Gray, N. S.; Sim, T. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl J. Med. Chem. 2010, 53, 5439-5448
39. Huang, W. S.; Shakespeare, W. C. An efficient synthesis of nilotinib (AMN107) Synthesis-Stuttgart 2007, 2121-2124
40. Jung, M. E.; Ouk, S.; Yoo, D.; Sawyers, C. L.; Chen, C.; Tran, C.; Wongvipat, J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC) J. Med. Chem. 2010, 53, 2779-2796
41. Niesen, F. H.; Berglund, H.; Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability Nat. Protoc. 2007, 2, 2212-2221
42. Wang, Y.; Shakespeare, W. C.; Huang, W. S.; Sundaramoorthi, R.; Lentini, S.; Das, S.; Liu, S.; Banda, G.; Wen, D.; Zhu, X.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Dalgarno, D.; Clackson, T.; Sawyer, T. K. Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 4907-4912
43. Bamborough, P.; Angell, R. M.; Bhamra, I.; Brown, D.; Bull, J.; Christopher, J. A.; Cooper, A. W.; Fazal, L. H.; Giordano, I.; Hind, L.; Patel, V. K.; Ranshaw, L. E.; Sims, M. J.; Skone, P. A.; Smith, K. J.; Vickerstaff, E.; Washington, M. N-4-Pyrimidinyl-1 H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics Bioorg. Med. Chem. Lett. 2007, 17, 4363-4368
44. Angell, R. M.; Angell, T. D.; Bamborough, P.; Brown, D.; Brown, M.; Buckton, J. B.; Cockerill, S. G.; Edwards, C. D.; Jones, K. L.; Longstaff, T.; Smee, P. A.; Smith, K. J.; Somers, D. O.; Walker, A. L.; Willson, M. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR Bioorg. Med. Chem. Lett. 2008, 18, 324-328
45. Graham Robinett, R.; Freemerman, A. J.; Skinner, M. A.; Shewchuk, L.; Lackey, K. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 5886-5893
46. Hynes, J., Jr.; Dyckman, A. J.; Lin, S.; Wrobleski, S. T.; Wu, H.; Gillooly, K. M.; Kanner, S. B.; Lonial, H.; Loo, D.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Shuster, D. J.; Yang, X.; Zhang, R.; Behnia, K.; Zhang, H.; Marathe, P. H.; Doweyko, A. M.; Tokarski, J. S.; Sack, J. S.; Pokross, M.; Kiefer, S. E.; Newitt, J. A.; Barrish, J. C.; Dodd, J.; Schieven, G. L.; Leftheris, K. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α mitogen-activated protein kinase inhibitors J. Med. Chem. 2008, 51, 4-16
47. Deak, H. L.; Newcomb, J. R.; Nunes, J. J.; Boucher, C.; Cheng, A. C.; DiMauro, E. F.; Epstein, L. F.; Gallant, P.; Hodous, B. L.; Huang, X.; Lee, J. H.; Patel, V. F.; Schneider, S.; Turci, S. M.; Zhu, X. N-(3-(Phenylcarbamoyl) arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR Bioorg. Med. Chem. Lett. 2008, 18, 1172-1176
48. Kufareva, I.; Abagyan, R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states J. Med. Chem. 2008, 51, 7921-7932
49. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat. Struct. Biol. 2002, 9, 268-272
50. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 2006, 5, 730-739
51. Manley, P. W.; Cowan-Jacob, S. W.; Fendrich, G.; Jahnke, W.; Fabbro, D. Nilotinib, in Comparison to Both Dasatinib and Imatinib, Possesses a Greatly Prolonged Residence Time When Bound to the BCR-ABL Kinase SH1 Domain. 53rd ASH Annual Meeting and Exposition, San Diego, CA, 2011.
52. Kitagawa, D.; Gouda, M.; Kirii, Y. Quick evaluation of kinase inhibitors by surface plasmon resonance using single-site specifically biotinylated kinases J. Biomol. Screening 2014, 19, 453-461
53. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 2004, 64, 6652-6659
54. Fabian, M. A.; Biggs, W. H., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336
55. Kumar, S. R.; Singh, J.; Xia, G.; Krasnoperov, V.; Hassanieh, L.; Ley, E. J.; Scehnet, J.; Kumar, N. G.; Hawes, D.; Press, M. F.; Weaver, F. A.; Gill, P. S. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer Am. J. Pathol. 2006, 169, 279-293
56. Stephenson, S. A.; Slomka, S.; Douglas, E. L.; Hewett, P. J.; Hardingham, J. E. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer BMC Mol. Biol. 2001, 2, 15
57. Castellano, G.; Reid, J. F.; Alberti, P.; Carcangiu, M. L.; Tomassetti, A.; Canevari, S. New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies Cancer Res. 2006, 66, 10709-10719
58. Adams, R. H. Vascular patterning by Eph receptor tyrosine kinases and ephrins Semin. Cell Dev. Biol. 2002, 13, 55-60
59. Martiny-Baron, G.; Holzer, P.; Billy, E.; Schnell, C.; Brueggen, J.; Ferretti, M.; Schmiedeberg, N.; Wood, J. M.; Furet, P.; Imbach, P. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis Angiogenesis 2010, 13, 259-267
60. Korff, T.; Augustin, H. G. Tensional forces in fibrillar extracellular matrices control directional capillary sprouting J. Cell Sci. 1999, 112 (Pt 19) 3249-3258